YnnoMed

YnnoMed

YnnoMed established a platform for the discovery and development of novel drugs, using computer-assisted and AI-integrated technology to aid in the identification of unique drug targets, rational drug design, hit screening, lead optimisation, biological evaluation, pharmacological and toxicity assessment. The use of AI-integrated technology allows us to increase rate of success, streamline the discovery process and significantly reduce costs in pre-clinical stages of drug R&D. Deployment of this technology has resulted in our successful identification of several promising first-in-class antimicrobial drug candidates. We also provide assistance on hit compound and “me-too” drug identification for other areas of biomedical research. By assisting in accelerating the R&D efforts of both academia and the pharmaceutical industry, our products and services are expected to enrich the antibiotic drug market.

Members

Dr. Xiao YANG
Dr. CHU Adrian Jun
Ms. LIN Lin
Mr. TSANG Tszfung
Dr. Cong MA

Website

–

Status

Graduated Team (2020 Spring Intake)

 

PI Centre

@2026 All Rights Reserved. The Chinese University of Hong Kong

Privacy Statement | Disclaimer

Graduation

PI teams could continue product development, establish a start-up venture, obtain investment or enter external incubation programmes, such as HKSTP’s INCUBATION and Cyberport’s CCMF.

Incubation

Our entrepreneurial consultant, together with mentors, will help PI teams on milestone execution. PI Centre will also host training and networking events.

Inception

Successful applicants will become PI Teams. Our entrepreneurial consultant will offer guidance on their milestone plans for the incubation period.

Application

PI Centre applications open twice a year. Applicants will be assessed and admitted by an Assessment Panel, convened by PI Centre’s Advisory Committee.